Evidence map›Paper›PMID 37007765›Full record

ReviewFrontiers in medicine2023

Unmet needs and perspectives in rheumatoid arthritis-associated interstitial lung disease: A critical review.

Anna Stainer, Antonio Tonutti, Maria De Santis, Francesco Amati, Angela Ceribelli, Gabriele Bongiovanni, Chiara Torrisi, Antonio Iacopino, Giuseppe Mangiameli, Stefano Aliberti and 1 more

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Evaluation of screening methods for preclinical interstitial lung disease associated with rheumatoid arthritis.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2025
    Article
  8. Article
  9. Article
  10. Anti-Frontiers in medicine · 2025
    Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. The Lung in Rheumatoid Arthritis-Friend or Enemy?International journal of molecular sciences · 2024
    Review
  17. Article
  18. Biomarker insights · 2024
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Anna StainerDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.
Antonio TonuttiDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.
Maria De SantisDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.
Francesco AmatiDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.
Angela CeribelliDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.
Gabriele BongiovanniDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.
Chiara TorrisiDepartment of Radiology, IRCCS Humanitas Research Hospital, Milan, Italy.
Antonio IacopinoDepartment of Radiology, IRCCS Humanitas Research Hospital, Milan, Italy.
Giuseppe MangiameliDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.
Stefano AlibertiDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.
Carlo SelmiDepartment of Biomedical Sciences, Humanitas University, Milan, Italy.
IRCCS Humanitas Research Hospital · ITHumanitas University · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by synovitis as the most common clinical manifestation, and interstitial lung disease (RA-ILD) represents one of the most common and potentially severe extra-articular features. Our current understanding of the mechanisms and predictors of RA-ILD is limited despite the demonstration that an early identification of progressive fibrosing forms is crucial to provide timely treatment with antifibrotic therapies. While high resolution computed tomography is the gold standard technique for the diagnosis and follow-up of RA-ILD, it has been hypothesized that serum biomarkers (including novel and rare autoantibodies), new imaging techniques such as ultrasound of the lung, or the application of innovative radiologic algorithms may help towards predicting and detecting early forms of diseases. Further, while new treatments are becoming available for idiopathic and connective tissue disease-associated forms of lung fibrosis, the treatment of RA-ILD remains anecdotal and largely unexplored. We are convinced that a better understanding of the mechanisms connecting RA with ILD in a subgroup of patients as well as the creation of adequate diagnostic pathways will be mandatory steps for a more effective management of this clinically challenging entity.

Indexed as

biomarkersclinical trialsimmunologyinterstitial lung diseaselung ultrasonographyprecision medicineprogressive pulmonary fibrosisrheumatoid arthritis

Identifiers

PMID37007765
PMCPMC10062456
OpenAlexW4327613850

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.